The complexity of 'harm reduction' with smokeless tobacco as an approach to tobacco control in low-income and middle-income countries

Tobacco Control

Volumn 21, Issue 2, 2012, Pages 245-251

  Ayo Yusuf, Olalekan A ^a,b   Burns, David M ^c  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b Human Development and Health ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DEVELOPING COUNTRY; EVIDENCE BASED MEDICINE; HARM REDUCTION; HEALTH PROMOTION; HUMAN; MARKETING; METHODOLOGY; SMOKELESS TOBACCO; SMOKING; SMOKING CESSATION;

DEVELOPING COUNTRIES; EVIDENCE-BASED MEDICINE; HARM REDUCTION; HEALTH PROMOTION; HUMANS; MARKETING; SMOKING; SMOKING CESSATION; TOBACCO, SMOKELESS;

EID: 84857338580     PISSN: 09644563     EISSN: 14683318     Source Type: Journal    
DOI: 10.1136/tobaccocontrol-2011-050367     Document Type: Article

References (80)

1. World Health Organization. WHO Report on the Global Tobacco Epidemic, 2008: The MPOWER Package. Geneva: WHO press, 2008.
2. Ezzati M, Lopez AD. Smoking and oral tobacco use. In: Ezzati M, Lopez AD, Rodgers A, et al. eds. Comparative Quantification of Health Risks for the Year 2000. Geneva: WHO, 2004:883-957. http://www.who.int/healthinfo/globalburdendisease/cra/en/ (accessed 3 Mar 2011).
3. Chaloupka FJ, Jha P, Corrao MA, et al. Global efforts for reducing the burden of smoking. Disease Management & Health Outcomes 2003;11:647-61.
4. WHO Framework Convention on Tobacco Control (FCTC). http://whqlibdoc.who.int/publications/2003/9241591013.pdf (accessed 3 Mar 2011).
5. Irvin JE, Brandon TH. The increasing recalcitrance of smokers in clinical trials. Nicotine Tob Res 2000;2:79-84.
6. Joseph AM, Hennrikus D, Thoele MJ, et al. Community tobacco control leaders' perceptions of harm reduction. Tob Control 2004;13:108-13.
7. Stratton K, Shetty P, Wallace R, et al, eds. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction. Washington, DC: National Academy Press, 2001.
8. Warner KE. Tobacco harm reduction: promise and perils. Nicotine Tob Res 2002;4 (Suppl 2):S61-71.
9. Hatsukami DK, Slade J, Benowitz NL, et al. Reducing tobacco harm: research challenges and issues. Nicotine Tob Res 2002;4(Suppl 2):S89-101.
10. Foulds J, Ramstrom L, Burke M, et al. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob Control 2003;12:349-59.
11. Ramström LM, Foulds J. Role of snus in initiation and cessation of tobacco smoking in Sweden. Tob Control 2006;15:210-14.
12. Mejia AB, Ling PM, Glantz SA. Quantifying the effects of promoting smokeless tobacco as a harm reduction strategy in the USA. Tob Control 2010;19:297-305.
13. Fox BJ, Cohen JE. Tobacco harm reduction: a call to address the ethical dilemmas. Nicotine Tob Res 2002;4(Suppl 2):S81-7.
14. Martin EG, Warner KE, Lantz PM. Tobacco harm reduction: what do the experts think? Tob Control 2004;13:123-8.
15. Roche AM. Harm reduction and smoking among indigenous Australians. Drug Alcohol Rev 1997;16:91-3.
16. Bedi R, Scully C. Tobacco control-debate on harm reduction enters new phase as India implements public smoking ban. Lancet Oncol 2008;9:1122-3.
17. Idris AM, Ibrahim SO, Vasstrand EN, et al. The Swedish snus and the Sudanese toombak: are they different? Oral Oncol 1998;34:558-66.
18. Gupta PC, Pednekar MS, Parkin DM, et al. Tobacco associated mortality in Mumbai (Bombay) India. Results of the Bombay cohort study. Int J Epidemiol 2005;34:1395-402.
19. Ayo-Yusuf OA, Reddy PS, Van den Borne BW. Association of snuff use with chronic bronchitis among South African women: implications for tobacco harm reduction. Tob Control 2008;17:99-104.
20. Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR). Opinion on: Health Effects of Smokeless Tobacco Products. http://www.tobaccoharmreduction.org/scenihr.pdf (accessed 4 May 2011).
21. International Agency for Research on Cancer. Smokeless Tobacco and Some Tobacco-specific N-nitrosamines. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 89. Lyon: IARC, 2007.
22. Stanfill SB, Connolly GN, Zhang L, et al. Global surveillance of oral tobacco products: total nicotine, unionized nicotine and tobacco-specific N-nitrosamines. Tob Control 2011;20:e2.
23. McNeil A, Bedi R, Islam S, et al. Level of toxins in oral tobacco products in the UK. Tob Control 2006;15:64-7.
24. Boffetta P, Hecht S, Gray N, et al. Smokeless tobacco and cancer. Lancet Oncol 2008;9:667-75.
25. Lee PN, Hamling J. Systematic review of the relation between smokeless tobacco and cancer in Europe and North America. BMC Med 2009;7:36.
26. World Health Organization. WHO Study Group on Tobacco Product Regulation. Report on Setting Regulatory Limits for Carcinogens In Smokeless Tobacco. Report on the Scientific Basis of Tobacco Product Regulation: Third Report of a WHO Study Group. WHO Technical Report Series No. 955. Geneva: WHOpress, 2009:23-8.
27. Lee PN. Circulatory disease and smokeless tobacco in Western populations: a review of the evidence. Int J Epidemiol 2007;36:789-804.
28. Boffeta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ 2009;339:b3060.
29. Yatsuya H, Folsom AR; ARIC Investigators. Risk of incident cardiovascular disease among users of smokeless tobacco in the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2010;172:600-5.
30. Hergens MP, Lambe M, Pershagen G, et al. Smokeless tobacco and the risk of stroke. Epidemiology 2008;19:794-9.
31. Teo KK, Ounpuu S, Hawken S, et al; INTERHEART Study Investigators. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006;368:647-58.
32. England LJ, Levine RJ, Mills JL, et al. Adverse pregnancy outcomes in snuff users. Am J Obstet Gynecol 2003;189:939-43.
33. Gupta PC, Subramoney S. Smokeless tobacco use and risk of stillbirth: a cohort study in Mumbai, India. Epidemiology 2006;17:47-51.
34. Wikström AK, Stephansson O, Cnattingius S. Tobacco use during pregnancy and preeclampsia risk: effects of cigarette smoking and snuff. Hypertension 2010;55:1254-9.
35. Steyn K, De Wet T, Saloojee Y, et al. The influence of maternal cigarette smoking, snuff use and passive smoking on pregnancy outcomes: the birth to ten study. Paediatr Perinat Epidemiol 2006;20:90-9.
36. Simen-Kapeu A, La Ruche G, Kataja V, et al. Tobacco smoking and chewing as risk factors for multiple human papillomavirus infections and cervical squamous intraepithelial lesions in two countries (Cote d'Ivoire and Finland) with different tobacco exposure. Cancer Causes Control 2009;20:63-70.
37. Tomar SL. Is use of smokeless tobacco a risk factor for cigarette smoking? The US experience. Nicotine Tob Res 2003;5:561-9.
38. Severson HH, Forrester KK, Biglan A. Use of smokeless tobacco is a risk factor for cigarette smoking. Nicotine Tob Res 2007;9:1331-7.
39. O'Connor RJ, Kozlowski LT, Flaherty BP, et al. Most smokeless tobacco use does not cause cigarette smoking: results from the 2000 National Household Survey on drug abuse. Addict Behav 2005;30:325-36.
40. Timberlake DS, Huh J, Lakon CM. Use of propensity score matching in evaluating smokeless tobacco as a gateway to smoking. Nicotine Tob Res 2009;11:455-62.
41. Stenbeck M, Hagquist C, Rosén M. The association of snus and smoking behaviour: a cohort analysis of Swedish males in the 1990s. Addiction 2009;104:1579-85.
42. Ayo-Yusuf OA, Connolly G. Role of Smokeless Tobacco Use in Smoking Initiation and Cessation Among South African Adolescents: a 4-year Longitudinal Study. Maryland: Oral presentation at the Society for Research on Nicotine & Tobacco, 2010. (Abstract # P18-2). http://www.srnt.org/conferences/past/2010/pdf/2010_SRNT_Proceedings.pdf (assessed 5 May 2011).
43. Lund KE, McNeill A, Scheffels J. The use of snus for quitting smoking compared with medicinal products. Nicotine Tob Res 2010;12:817-22.
44. Tønnesen P, Mikkelsen K, Bremann L. Smoking cessation with smokeless tobacco and group therapy: an open, randomized, controlled trial. Nicotine Tob Res 2008;10:1365-72.
45. Lindström M, Isacsson SO; Malmö Shoulder-Neck Study Group. Smoking cessation among daily smokers, aged 45-69 years: a longitudinal study in Malmö, Sweden. Addiction 2002;97:205-15.
46. Gilljam H, Galanti MR, Pharmacia AB; Swedish Cancer Society. Role of snus (oral moist snuff) in smoking cessation and smoking reduction in Sweden. Addiction 2003;98:1183-9.
47. Lindström M. Nicotine replacement therapy, professional therapy, snuff use and tobacco smoking: a study of smoking cessation strategies in southern Sweden. Tob Control 2007;16:410-16.
48. Lundqvist G, Sandström H, Ohman A, et al. Patterns of tobacco use: a 10-year follow-up study of smoking and snus habits in a middle-aged Swedish population. Scand J Public Health 2009;37:161-7.
49. Carpenter CM, Connolly GN, Ayo-Yusuf OA, et al. Developing smokeless tobacco products for smokers: an examination of tobacco industry documents. Tob Control 2009;18:54-9.
50. McClave-Regan AK, Berkowitz J. Smokers who are also using smokeless tobacco products in the US: a national assessment of characteristics, behaviours and beliefs of 'dual users'. Tob Control 2011;20:239-42.
51. O'Connor RJ, Norton KJ, Bansal-Travers M, et al. US smokers' reactions to a brief trial of oral nicotine products. Harm Reduct J 2011;8:1.
52. Tomar SL, Alpert HR, Connolly GN. Patterns of dual use of cigarettes and smokeless tobacco among US males: findings from national surveys. Tob Control 2010;19:104-9.
53. Klesges RC, Sherrill-Mittleman D, Ebbert JO, et al. Tobacco use harm reduction, elimination, and escalation in a large military cohort. Am J Public Health 2010;100:2487-92.
54. Rantao M, Ayo-Yusuf OA. Dual use of cigarettes and smokeless tobacco among South African adolescents. Am J Health Behav 2012;36:124-33.
55. Global Adult Tobacco Survey (GATS) India: 2009-2010. http://www.searo.who.int/LinkFiles/Regional_Tobacco_Surveillance_System_GATS_India.pdf (accessed 5 May 2011).
56. Desalu OO, Iseh KR, Olokoba AB, et al. Smokeless tobacco use in adult Nigerian population. Niger J Clin Pract 2010;13:382-7. http://www.njcponline.com/temp/NigerJClinPract134382-535445_145224.pdf (accessed 5 Sep 2011).
57. Usmanova G, Neumark Y, Baras M, et al. Patterns of adult tobacco use in Uzbekistan. Eur J Public Health. Published Online First: 9 September 2011. doi:10.1093/eurpub/ckr125.
58. Norberg M, Lundqvist G, Nilsson M, et al. Changing patterns of tobacco use in a middle-aged population: the role of snus, gender, age, and education. Glob Health Action 2011;4. doi:10.3402/gha.v4i0.5613.
59. Engström K, Magnusson C, Galanti MR. Socio-demographic, lifestyle and health characteristics among snus users and dual tobacco users in Stockholm County, Sweden. BMC Public Health 2010;10:619.
60. Frost-Pineda K, Appleton S, Fisher M, et al. Does dual use jeopardize the potential role of smokeless tobacco in harm reduction? Nicotine Tob Res 2010; 12:1055-67.
61. Rosendahl KI, Galanti MR, Gilljam H. Trajectories of smokeless tobacco use and of cigarette smoking in a cohort of Swedish adolescents: differences and implications. Nicotine Tob Res 2008;10:1021-7.
62. Shiffman S, Gitchell J, Rohay JM, et al. Smokers' preferences for medicinal nicotine vs smokeless tobacco. Am J Health Behav 2007;31:462-72.
63. Wilson N, Borland R, Weerasekera D, et al. Smoker interest in lower harm alternatives to cigarettes: national survey data. Nicotine Tob Res 2009;11:1467-73.
64. Gartner CE, Jimenez-Soto EV, Borland R, et al. Are Australian smokers interested in using low-nitrosamine smokeless tobacco for harm reduction? Tob Control 2010;19:451-6.
65. Timberlake DS. Are smokers receptive to using smokeless tobacco as a substitute? Prev Med 2009;49:229-32.
66. Connolly GN. The marketing of nicotine addiction by oral snuff manufacturer. Tob Control 1995;4:73-9.
67. Zhu SH, Wang JB, Hartman A, et al. Quitting cigarettes completely or switching to smokeless tobacco: do US data replicate the Swedish results? Tob Control 2009;18:82-7.
68. Alternative to Cigarettes Unrolled. http://articles.timesofindia.indiatimes.com/2002-02-23/pune/27122004_1_snus-oral-cancer-tobacco (accessed 14 Nov 2011).
69. Chapman S. Public Health Advocacy and Tobacco Control: Making Smoking History. 1st edn. Oxford: Blackwell, 2007.
70. Curry LE, Pederson LL, Stryker JE. The changing marketing of smokeless tobacco in magazine advertisements. Nicotine Tob Res 2011;13:540-7.
71. Timberlake DS, Pechmann C, Tran SY, et al. A content analysis of Camel snus advertisements in print media. Nicotine Tob Res 2011;13:431-9.
72. Gartner CE, Hall WD, Chapman S, et al. Should the health community promote smokeless tobacco (snus) as a harm reduction measure? PLoS Med 2007;4:e185.
73. Peer N, Bradshaw D, Laubscher R, et al. Trends in adult tobacco use from two South African demographic and health surveys conducted in 1998 and 2003. S Afr Med J 2009;99:744-9.
74. Nilsson S, Carstensen JM, Pershagen G. Mortality among male and female smokers in Sweden: a 33 year follow up. J Epidemiol Community Health 2001;55:825-30.
75. Nordgren P, Ramstrom L. Moist snuff in Swedendtradition and evolution. Br J Addict 1990;85:1107-12.
76. Tomar SL, Connolly GN, Wilkenfield J, et al. Declining smoking in Sweden: is Swedish match getting the credit for Swedish tobacco control's efforts? Tob Control 2003;12:368-71.
77. World Health Organization (WHO) Country Office for Bangladesh. Global Adult Tobacco Survey: Bangladesh Report. Bangladesh, 2009. http://www.whoban.org/pdf/Global%20Adult%20Tobacco%20Survey%20Bangladesh%20Report%202009.pdf (accessed 15 Nov 2011).
78. Murukutla N, Turk T, Prasad CV, et al. Results of a national mass media campaign in India to warn against the dangers of smokeless tobacco consumption. Tob Control 2012;21:12-17.
79. WHO Report on the Global Tobacco Epidemic, 2011. http://www.who.int/tobacco/global_report/2011/appendix_viii/en/index.html (accessed 15 Nov 2011).
80. Yang GH, Li Q, Wang CX, et al. Findings from 2010 global adult tobacco survey: implementation of MPOWER policy in China. Biomed Environ Sci 2010;23:422-9.